mHSPC
mHSPC
Metastatic hormone-sensitive prostate cancer
Advertisement
David Ambinder, MDmHSPC | February 23, 2023
Is it possible to avoid or delay systemic therapy for patients with oligometastatic prostate cancer? A new study suggests so.
Read More
Zachary BessetteASCO GU Symposium 2023 | February 16, 2023
An analysis highlighted real-world treatment of patients with mHSPC in the community who received at least 1 line of therapy.
Tanya Dorff, MDmHSPC | February 13, 2023
Tanya Dorff, MD, shares the barriers to utilizing PARP inhibitors plus AR-targeted agents in early prostate cancer settings.
Matthew Deek, MDmHSPC | January 31, 2023
Dr. Deek shares what research should be done to better personalize care for patients with oligometastatic prostate cancer.
Matthew Deek, MDmHSPC | January 31, 2023
Dr. Deek shares what “high-risk mutation” signified in his study and how patients with “high-risk mutation” should be ...
Matthew Deek, MDNext-Generation Imaging | January 31, 2023
Dr. Deek shares how PSMA imaging used in both the STOMP and ORIOLE trials.
Matthew Deek, MDmHSPC | January 31, 2023
Dr. Deek shares how he evaluated long-term outcomes of MDT in om CSPC in both the ORIOLE and STOMP trials.
Emily MenendezRLT-PSMA | January 12, 2023
While PSMA-RLT is typically used during later disease stages, patients in earlier disease stages may benefit as well.
Emily MenendezmCRPC | January 4, 2023
Liquid biopsy of CTCs may serve as an effective prediction biomarker for docetaxel response in patients with CRPC and mHSPC.
Zachary BessettemHSPC | December 7, 2022
High testosterone levels measured by a liquid chromatography-tandem mass spectrometry assay may predict castration response.
The UromigosUromigos Live and Unplugged | November 4, 2022
Daniel George, MD, Duke University School of Medicine, gives us insight on what to expect from the future of mHSPC treatment.
The UromigosUromigos Live and Unplugged | November 4, 2022
Neeraj Agarwal, MD, Professor of Medicine, gives his outlook on the future of cancer care and treatment for mHSPC in 2027.
The UromigosUromigos Live and Unplugged | November 4, 2022
Michael Morris, MD, of Memorial Sloan Kettering Cancer Center gives his predictions for the future of mHSPC treatment.
Akhil Abraham Saji, MDJournal | October 24, 2022
Abiraterone acetate + prednisolone is compared to enzalutamide + AAP for mHSPC cancer starting androgen-deprivation therapy.
Leah LawrenceProstate Cancer | October 18, 2022
Zoledronic acid did not improve survival outcomes in patients outside of metastatic castration-resistant disease.
Patrick DalyESMO 2022 | September 12, 2022
Late-breaking data from 2 randomized phase 3 trials that followed STAMPEDE protocol were presented at the ESMO Congress 2022.
Cecilia BrownmHSPC | August 9, 2022
The FDA has approved the use of darolutamide in combination with docetaxel for metastatic hormone-sensitive prostate cancer.
GU Oncology Now EditorsmCRPC | June 2, 2022
Researchers evaluate the frequency of germline DDRg mutations in metastatic prostate cancer patients of different ancestries.
Advertisement
Advertisement
Advertisement